Martin Crump recently authored an eBook regarding Risperdal, a psychiatric medication marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The book discusses the history of Risperdal, Janssen’s Pharmaceuticals’ efforts to market the drug to minors, and Risperdal’s link to gynecomastia (enlarged male breasts).
Janssen Pharmaceuticals obtained approval from the FDA in 1993 to market Risperdal to patients with bi-polar and schizophrenia. Janssen was later denied a request for pediatric use of the drug in 1997. Despite the denial, Janssen marketed Risperdal to doctors for use by minors from 1994 until 2006, when limited pediatric approval was obtained. In 2013, Janssen Pharmaceuticals pain a $2.2 billion dollar settlement with the Department of Justice to resolve criminal and civil fines arising out of the illegal marketing of Risperdal.
Davis & Crump is handling claims on behalf of men and boys who have suffered gynecomastia. Contact Davis & Crump at 800-277-0300 or email us at firstname.lastname@example.org.